This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Glaxosmithkline Intellectual Property Development Limited. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: The Innovative Contributions of Sarah Gerhart
Introduction
Sarah Gerhart is a notable inventor based in Collegeville, PA (US). She has made significant strides in the field of cancer treatment through her innovative research and development. Her work focuses on the combination of specific protein arginine methyltransferase inhibitors, which has the potential to enhance therapeutic outcomes for patients.
Latest Patents
Sarah Gerhart holds 1 patent for her invention titled "Combination therapy." This invention provides a combination of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The methods described in her patent aim to treat cancer in humans by administering these inhibitors alongside a pharmaceutically acceptable carrier or diluent. Additionally, her invention includes a pharmaceutical composition that comprises a therapeutically effective amount of both Type I and Type II PRMT inhibitors.
Career Highlights
Sarah Gerhart is associated with GlaxoSmithKline Intellectual Property Development Limited, where she contributes her expertise in pharmaceutical development. Her work is pivotal in advancing cancer treatment methodologies, showcasing her commitment to improving patient care through innovative solutions.
Collaborations
Sarah has collaborated with notable colleagues, including Helai Mohammad and Niyant Shah, to further her research and development efforts. Their combined expertise enhances the potential impact of their work in the field of cancer therapy.
Conclusion
In summary, Sarah Gerhart's contributions to the field of cancer treatment through her innovative patent demonstrate her dedication to advancing medical science. Her work not only reflects her expertise but also holds promise for improving therapeutic strategies for cancer patients.